Author

D. J. Lynn

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Assay:metabolomics· 2 Assay:proteomics· 2

Frequent Co-Authors

L. M. Butler· 4 shared C. Y. Mah· 3 shared J. Dehairs· 3 shared J. V. Swinnen· 3 shared L. A. Selth· 3 shared M. M. Centenera· 3 shared M. Moldovan· 3 shared S. Irani· 3 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

L. M. Butler

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Cardiovascular symptoms of PASC are associated with trace-level cytokines that affect the function of human pluripotent stem cell derived cardiomyocytes

J. Sinclair, C. Vedelago, F. Ryan, M. Carney, M. Redd, M. Lynn, B. Grubor-Bauk, Y. Cao, A. Henders, K. Y. Chew, D. Gilroy, K. Greaves, L. Labzin, L. Ziser, K. Ronacher, , K. Short

This study identifies trace-level cytokines in PASC patients linked to cardiovascular symptoms and shows their impact on cardiomyocyte function using nanotechnology detection.

bioRxiv · Apr 11, 2024 · PreprintMicrobiology

Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer

C. Y. Mah, A. D. T. Nguyen, T. Niijima, M. Helm, J. Dehairs, F. J. Ryan, N. Ryan, I. G. Mills, J. V. Swinnen, D. J. Lynn, Z. D. Nassar, L. M. Butler

This study identifies DECR2 as a key driver of treatment resistance in advanced prostate cancer by regulating lipid metabolism and cell cycle progression.

bioRxiv · Nov 5, 2022Cancer Biology

Lipidomic profiling of clinical prostate cancer reveals targetable alterations in lipid composition

L. M. Butler, C. Y. Mah, J. Machiels, A. D. Vincent, S. Irani, S. Mutuku, X. Spotbeen, M. Bagadi, D. Waltregny, M. Moldovan, J. Dehairs, F. Vanderhoydonc, K. Bloch, R. Das, J. Stahl, , J. V. Swinnen

The paper profiles lipidomes in prostate cancer tissues and identifies targetable lipid alterations linked to AR signaling and therapeutic response.

bioRxiv · Oct 27, 2020Cancer Biology

A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth

J. L. Gillis, J. A. Hinneh, N. K. Ryan, S. Irani, M. Moldovan, R. K. Shrestha, L.-E. Quek, A. J. Hoy, J. Holst, M. M. Centenera, I. G. Mills, D. J. Lynn, L. A. Selth, L. M. Butler

This study identifies a feedback loop between the androgen receptor and 6PGD that drives prostate cancer growth and shows that targeting both improves therapeutic efficacy.

bioRxiv · Sep 2, 2020Cancer Biology

DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis

Z. D. Nassar, C. Y. Mah, J. Dehairs, I. J. G. Burvenich, S. Irani, M. M. Centenera, R. K. Shrestha, M. Moldovan, A. S. Don, A. M. Scott, L. G. Horvath, D. J. Lynn, L. A. Selth, A. J. Hoy, J. V. Swinnen, L. M. Butler

This study identifies DECR1 as an androgen-repressed gene that promotes prostate cancer cell survival by facilitating PUFA oxidation and preventing ferroptosis.

bioRxiv · Dec 6, 2019Cancer Biology